This document provides information on Intensified Mission Indradhanush 4.0 (IMI 4.0), India's immunization drive. It discusses immunization coverage trends from NFHS surveys from 2005-2021. It shows that full immunization coverage in India has increased from 43.5% to 76.4% over this period. However, 6 states saw decreases in coverage from NFHS-4 to NFHS-5. The document outlines programmatic challenges during COVID-19 like disrupted outreach and decreased uptake. It provides details of the IMI 4.0 plan like its timeline in 3 phases, target populations, focus areas, and accountability framework at national, state and district levels. Microplanning, communication and
The microplan is developed prior to the polio round by the Government and WHO-NPSP with support from partners at block, district and state levels. It gives a detailed plan of the house-to-house activity with team numbers, names of team members, supervisors, including influencers and routine immunization indicators.
Webinar : Adapting your advocacy to COVID-19 health crisisIRC
The COVID-19 pandemic is forcing development programmes to rapidly readjust their advocacy strategy to support local or national governments in their emergency planning. The Watershed empowering citizens programme organised a webinar attended by over 60 participants on 15 April 2020, to discuss and learn about: ways to adapt advocacy approaches in time of COVID-19; practical examples of shifting activities at national and local levels; ways to reach your target audience while social distancing; ways to adapt your messaging, keeping Watershed priorities through the lens of COVID-19.
This report includes the webinar Powerpoint presentations and some recommendations based on the Q&A session. The titles and authors of the presentations are: "Why is strong advocacy essential during a crisis?" by Evita Rosenberg (IRC); "Watershed Bangladesh : adapting advocacy approaches during COVID 19 outbreak" by Ranjan Kumar Ghose (WaterAid Bangladesh); and "Adapting advocacy approaches in Kenya "by Patrick Mwanzia (Simavi Kenya).
The mission of the Sexually Transmitted Diseases (STD) Control Program is to reduce the occurrence of STDs through disease surveillance, case and outbreak investigation, screening, preventive therapy, outreach, diagnosis, case management, and education.
NATIONAL AIDS CONTROL PROGRAMME(NACP) PPT BY KRITIKA.pptxKritikaDhawan9
Acquired immunodeficiency syndrome (AIDS) is a chronic , potentially life, threating condition caused by the human immunodeficiency virus(HIV), a human retrovirus . By, damaging your immune system , HIV interferes with your body's ability to fight infection and disease.
HIV uses the machinery of the CD4 cells to multiply and spread throughout the body .
The microplan is developed prior to the polio round by the Government and WHO-NPSP with support from partners at block, district and state levels. It gives a detailed plan of the house-to-house activity with team numbers, names of team members, supervisors, including influencers and routine immunization indicators.
Webinar : Adapting your advocacy to COVID-19 health crisisIRC
The COVID-19 pandemic is forcing development programmes to rapidly readjust their advocacy strategy to support local or national governments in their emergency planning. The Watershed empowering citizens programme organised a webinar attended by over 60 participants on 15 April 2020, to discuss and learn about: ways to adapt advocacy approaches in time of COVID-19; practical examples of shifting activities at national and local levels; ways to reach your target audience while social distancing; ways to adapt your messaging, keeping Watershed priorities through the lens of COVID-19.
This report includes the webinar Powerpoint presentations and some recommendations based on the Q&A session. The titles and authors of the presentations are: "Why is strong advocacy essential during a crisis?" by Evita Rosenberg (IRC); "Watershed Bangladesh : adapting advocacy approaches during COVID 19 outbreak" by Ranjan Kumar Ghose (WaterAid Bangladesh); and "Adapting advocacy approaches in Kenya "by Patrick Mwanzia (Simavi Kenya).
The mission of the Sexually Transmitted Diseases (STD) Control Program is to reduce the occurrence of STDs through disease surveillance, case and outbreak investigation, screening, preventive therapy, outreach, diagnosis, case management, and education.
NATIONAL AIDS CONTROL PROGRAMME(NACP) PPT BY KRITIKA.pptxKritikaDhawan9
Acquired immunodeficiency syndrome (AIDS) is a chronic , potentially life, threating condition caused by the human immunodeficiency virus(HIV), a human retrovirus . By, damaging your immune system , HIV interferes with your body's ability to fight infection and disease.
HIV uses the machinery of the CD4 cells to multiply and spread throughout the body .
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
4. M i g r a n t P o p u l a t i o n s
R a p i d U r b a n i z a t i o n
Programmatic Challenges
A c c e s s i b i l i t y
A c c e p t a n c e
S l o w P r o g r e s s E q u i t y I s s u e s
5. Programmatic Challenges- COVID-19
Due to COVID-19 containment many outreach
sessions not being held, resulting in a fall in
immunization coverages.
Since Anganwadi centres & schools are closed RI
sessions are being organized at alternate session sites
affecting the uptake of services.
Overlap of work due to engagement of ANM and
frontline workers in COVID containment and COVID
vaccination
Large scale movement of migrant population
Hesitancy among caregivers to take their children to
healthcare facilities due to fear of exposure to COVID-
19.
6. Drop in Immunization Coverage
• Globally 2.3 crore children <1 year
old left unvaccinated even with
basic vaccines
• India ranks first with most
un/partially vaccinated children
IMI- 4.0 6
7. Immunization strengthening during COVID-19 pandemic
• Health Services including Immunization deemed as essential
services – MHA order issued
• Guidelines for delivering Immunization services during
COVID-19 outbreak disseminated by MoHFW
• Routine Immunization
• Polio SIAs
• Surveillance for Vaccine Preventable Diseases
• Reviews held with States/ UTs to discuss challenges being
faced during the pandemic and the necessary measures
taken to ensure immunization services
12. Timeline – 3 Phases in 3 Months
• In view of the involvement in Covid vaccination and Covid surge the earlier guidance is
relaxed
• Unlike in the past, each round will be conducted for seven days, including RI days,
Sundays, and public holidays
• Timings: Flexible timing; as agreed with community
IMI- 4.0 12
Round Date (2022)
1 7th February onwards
2 7th March onwards
3 4th April onwards
13. Target Population
• The target beneficiaries include,
• Un/Partially vaccinated children less than 2 years (0 to 23 Months)
• Unvaccinated or partially vaccinated pregnant women
• Pregnant women target includes all those who are currently pregnant on the day of
headcount survey and due for vaccination either with primary or booster dose for Td.
• The target children include all those born in or after February 2020 and due for one
or more vaccines
IMI- 4.0 13
14. Focus area
IMI- 4.0 14
• Areas with disrupted RI services due to COVID-19 pandemic
• High-risk areas: Migratory population, Nomadic sites, Brick Kilns Construction Sites Others
• New-born who was delivered at home.
• Villages/areas with Vacant sub centers, two or more consecutive missed routine immunization sessions.
• Hard to reach and areas with vaccine hesitancy
• Urban areas specially slums,
• Areas with outbreak of Measles, and other VPDs,
• Areas like orphanage, prisons, red-light areas, riverine areas, migration for agriculture etc.
• Tribal areas
• Other difficult areas: Areas hit by natural calamities (e.g., flood). The areas under social/political/or other
conflicts need additional administrative support.
15. IMI session planning
• Outreach and mobile sessions
• Criteria for selection of session site:
o Closer to the community
o Easily accessible and information reachable to community in advance
o Acceptable by the community
o Highly visible to people
o Suitable for Covid situation
IMI- 4.0 15
All efforts need to be made to ensure inclusion of all settlements including urban,
periurbal, rural and and temporary population at fringes of the village
16. Microplanning
Target of at least
90% FIC
Identification of beneficiaries missed
during COVID-19 pandemic
Key strategies and activities
During campaign: Intensive
monitoring and supervision
Communication
Planning
Governance and Multi-
sectoral collaboration
System
Strengthening
Follow COVID appropriate
behaviors at sessions
17. Accountability Framework
• MoHFW for overall guidance and review
• Training/Orientation of state health officials
• Communication strategy, prototype of IEC
materials
National
• State Steering Committee
• State Task Force for Immunization
• State review committee
• State level training of all district level master
trainers
State
• District/ City Task Force for Immunization (DTFI/CTFI)
• District Review Committee
• District health official as nodal officer for each
block/Urban units
• Distribution of funds, vaccines, IEC materials Logistics
to blocks/Urban units
District
/
City
• Block task force (BTF) headed by BDO
• Block review committee to review progress and ensure
timeliness
• Timely distribution of funds, IEC materials, logistics
and training of HW
• Micro planning with adequate HR allocation
Block
IMI- 4.0 17
18. State Level
• State Steering Committee meeting: once for inter-departmental coordination
• Meeting of State Task Force for Immunization: before and immediately after both
rounds
• State Workshop: Build capacity of key officials from IMI districts, preferably through
virtual platforms (One day)
• Media Sensitization Meeting (Half day)
• Review of districts for preparedness: Principal Secretary/ MD-NHM to review
preparedness of IMI districts before each round (Half day)
20. District Level
Task Force Participants Function Frequency
District Task force for
Immunization (DTFI)
Chairperson: District
magistrate / collector
Member secretary:
District
Immunization Officer
Responsibility: CS / Chief Medical Officer Reviews:
sensitize the stake holders, plan,
review the progress, strengthen
interdepartmental coordination,
identify the bottle necks, and
resolve the issues
Review the preparedness,
performance in between rounds
At least twice
before IMI 2022
and once
between rounds
District Task force for
Urban Immunization -
DTFU (I)
Chairperson: District
magistrate / collector
Member secretary:
District Medical and
Health Officer/CMO
Municipal Commissioner, DIO, District
coordinator/nodal officer NUHM,
Medical superintendent from DH,
District Development Officer, District
Education Officer, District Project Officer
ICDS, District Public Relation Officer,
Municipal Health Officer
Critically review the Immunization
progress, identify gaps, and decide
strategic actions to improve RI
coverage.
At least twice
before IMI 2022
and once
between rounds.
21. District Level
Group/ Workshop Participants Function Frequency
District review
committee Headed by
CMO/CS
Members include nodal officers,
district officials of key departments,
representatives of district level
partners, and CSOs.
Review micro plan,
Develop communication strategy,
Ensures timely reporting formats,
Monitor vaccine and logistics supply chain and cold
chain management.
Availability and distribution of funds and logistics
District workshop Training of medical officers:
Participants:
Two per block / urban planning unit (MOIC and one MO)
District Program Manager (NHM), district IEC consultant, district ASHA coordinator, district
cold chain handler, district data manager, district M&E coordinator (NHM), district accounts
manager (NHM)
One day
Training of Program / Accounts managers
Block program and accounts managers
DIO, District Program Manager, Master trainer (MO/District training officer), partner
agencies
One Hour
Training of Data Handlers Half a day
Training of cold chain handlers Half a day
Media sensitization workshop: to sensitize media person, media coverage, demand generation,
and to resolve their queries.
Half a day
22. Block/ City Level
• Identification of Supervisors: in blocks/ planning units
• Meeting of Block/ Urban Task Force for Immunization: one each before, during and
immediately after each round
• Training of health workers: Build capacity of ANMs, LHVs and Health Supervisors
(One day for each session)
• Orientation of Mobilizers: ASHAs and AWWs (Half day for each workshop)
• Development of microplans including Communication plan
• Monitoring of Communication activities
• Daily Evening Review Meeting: During implementation phase
23. Village/ Session Site Level
• Head Count Survey and preparation of due-lists
• Appropriate session site/s identification by ANM/ASHA
• Display of IEC material at strategic sites
• Meeting with Panchayat representative for involvement and support in social
mobilization - utilize meetings for Gram Swaraj Abhiyan
• Immunization session/s to be conducted on pre-defined dates
• Mobilization of beneficiaries to session sites by NYK, NSS, NCC, local volunteers and
PRIs
24. Microplanning
IMI 4.0 sessions are planned across seven days including RI
days/ COVID vaccination days
Focus on containment zones where some sessions were not
held, pockets of migrants who may have migrated during
lockdown
Flexible session timings, if required, specially in urban slums
Deployment of mobile teams, if required, to cover sparsely
populated settlements
Ensure that target is updated prior to the sessions and the
same is uploaded on the reporting portal for IMI 3.0
25. • Step-1: Identification of influencers: Identify the influencers in the catchment area. Influencers can be
gram Pradhan, community or religious leaders, teachers, NGO members, or ward members, counsellors etc.
• Step-2: Identify best venue, time, date/day: To be decided in consensus with the influencer.
• Step 3: Due listing of beneficiaries: The due list of beneficiaries is to be informed to the leaders of the
community (elderly, religious leaders, gram Pradhan etc.). The leaders of the community may be encouraged
to certify that all the children and pregnant women due for any vaccination have been captured in the due
list.
• Step-4: Update micro plans to conduct sessions as per community needs
• Step-5: Engage community leadership for mobilization
IMI- 4.0
New Activity Proposed
‘Vaccination on Demand’ in urban areas
26. • Display communication materials on COVID appropriate behaviors
• Availability of handwashing/ sanitization station for beneficiaries/
caregivers
• Vaccination team to wear 3 layer surgical mask
• Screen beneficiaries for flu-like symptoms
• Avoid crowding, ensure physical distancing of “2 gaz”
• Sanitize hands after vaccinating every beneficiary
• Provide messages to caregivers/ beneficiaries
• Disinfect seating space and equipment after completion of session
Infection Prevention & Control at Session Site
Staff to be trained on screening beneficiaries and
parents for Flu like symptoms